TABLE 2

Response Assessments, Excluding Brain Lesions, in 20 Patients with Metastatic Melanoma Receiving ICI Therapies

		Response at SCAN-2 (21–28 d)				Response at SCAN-3 (∼4 mo)
Patient no.	Treatment	RECIST 1.1	irRC	PERCIST	EORTC	RECIST 1.1	irRC	PERCIST	EORTC	Best overall response at ≥ 4 mo (RECIST 1.1)	Duration of observation(wk)^*	Best overall response before SCAN-3 (RECIST 1.1)^†
1	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	10	—
2	Ipilimumab	SD	PD	SMD	SMD	SD	SD	PMR	PMR	SD > 6 mo	51	—
3	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	15	—
4	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	15	—
5	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	18	—
6	BMS-936559	SD	SD	PMR	PMR	PD	PD	PMD	PMD	PD	23	uSD at 6 wk, PD at 12 wk
7	BMS-936559	SD	SD	SMD	SMD	PD	PD	PMD	PMD	PD	18	—
8	BMS-936559	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	18	uSD at 6 wk, PD at 12 wk
9	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	16	—
10	Ipilimumab	SD	SD	PMD	PMD	PD	PD	PMD	PMD	PD	17	—
11	Ipilimumab	SD	SD	PMD	PMD	CR	CR	PMR	PMR	CR	184	—
12	Ipilimumab	SD	SD	PMR	PMR	PD	PD	SMD	SMD	PD	17	—
13	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	16	—
14	Ipilimumab	SD	SD	SMD	PMD	PR	PR	PMR	PMR	PR	28	—
15	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	19	—
16	Ipilimumab	SD	SD	PMD	PMD	PR	SD	PMD	SMD	PR	40	—
17	Ipilimumab	PR	PR	SMD	PMR	CR	CR	PMR	PMR	CR	31	—
18	Nivolumab	SD	SD	PMR	SMD	PD	SD	PMD	PMD	PD	23	SD at 8 and 15 wk
19	Ipilimumab	PD	PD	PMD	PMD	PD	PD	PMD	PMD	PD	17	—
20	Ipilimumab	PD	PD	PMD	PMD	PD	SD	PMD	PMD	PD	16	—

↵* Duration of observation is calculated from time of first administration of ICI therapy on this trial. Patients who received ipilimumab were treated with maximum of 4 doses and observed thereafter. Patients who received anti–PD-1/PD-L1 continued to receive therapy until disease progression.
↵† Standard of care on-treatment radiographic assessments performed between SCAN-2 and SCAN-3 for 3 patients demonstrated transient disease stability. Their responses are characterized in last column.
PD = progressive disease; PMD = progressive metabolic disease; SD = stable disease; SMD = stable metabolic disease; PMR = partial metabolic response; PR = partial response; u = unconfirmed, seen only on 1 set of scans; CR = complete response.
Responses based on 4 criteria in 20 patients with metastatic melanoma after receiving ipilimumab (anti–CTLA-4), nivolumab (anti–PD-1), or BMS-936559 (anti–PD-L1). ¹⁸F-FDG PET/CT imaging was performed before therapy (SCAN-1), again between days 21 and 28 (SCAN-2), and at approximately 4 mo posttreatment initiation (SCAN-3).